|
KMID : 0869620120290030324
|
|
Journal of Korean Society of Hospital Pharmacists
2012 Volume.29 No. 3 p.324 ~ p.337
|
|
|
Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
|
|
Heo Hoon
Choi Ji-Seon
Im Hyun-Jeong
Chung Seon-Young
In Yong-Won
Lee Young-Mee
Park Young-Suk
|
|
|
Abstract
|
|
|
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor
(VEGF). It has been suggested that hypertension could be due to capillary rarefaction and
decreased nitric oxide synthesis caused by inhibition of the VEGF pathway. Based on this
hypothesis, we analyzed the possible association between bevacizumab-induced hypertension and clinical outcome in metastatic colorectal cancer (mCRC) patients treated with bevacizumab.
We conducted a retrospective chart review of patients with mCRC treated with bevacizumab at
Samsung Medical Center, from January to December 2009. Blood pressure was increased, according to common toxicity criteria for adverse events (CTCAE) version 4.0 scale.
A total of 102 mCRC patients were eligible and 30 patients (29.4%) developed grade 2-3 hypertension.
A complete or partial response was observed in 19 of the 30 (63.3%) patients with evacizumab-related hypertension, and in 20 of the 72 (27.8%) patients with no hypertension (p = 0.001). Patients who developed hypertension showed a longer median progression-free survival (36.6 weeks) when compared with patients without hypertension (28.1 weeks), but this difference was not statistically significant (p = 0.149).
Our results suggest that bevacizumab-induced hypertension may be a potential surrogate bio-marker of the clinical outcome in mCRC patients treated with bevacizumab.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Hypertension, Clinical outcome, Surrogate biomarker, Metastatic colorectal cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|